Funding:

Novartis

Description

To assess early phase safety and tolerability of converting from approved oral and injectable disease-modifying therapies for relapsing MS to siponimod. The results of this study will guide clinically relevant decisions related to the transition from frequently used therapies to siponimod and provide clinically relevant data on safety and tolerability for healthcare providers who are considering converting people with MS from currently approved therapies to siponimod.